close


close
SYNVISC packaging
genzyme corporationresearchgenzyme websites
Information for patientsContact Us
HomeAbout SYNVISCClinical Info and ResearchReimbursement ResourcesOrdering SYNVISCPatient Education
SYNVISC

Why choose SYNVISC?

Compare SYNVISC with other viscosupplements.

View comparison chart

About SYNVISC®

SYNVISC is a viscosupplement that can offer your patients up to 6 months of knee pain relief with only 3 injections, none of the GI or cardiovascular safety issues associated with oral medications, and double the pain relief when added to standard treatment, such as diet, exercise, acetaminophen, and NSAIDs.*

In this section, learn why SYNVISC may be a smart choice for your patients with osteoarthritis (OA) of the knee who are not getting enough relief from nonpharmacologic therapy and simple analgesics.

*Precise placement of the injection into the joint space must be achieved in order to optimize efficacy and minimize adverse reactions. The knee joint should be aspirated before the SYNVISC injection.




Important Safety Information

SYNVISC® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g., acetaminophen. In clinical trials, the most commonly reported adverse events were transient local pain, swelling, and/or effusion in the injected knee. In some cases, these symptoms have been extensive. Other side effects such as rash have been reported rarely.

SYNVISC is contraindicated in patients with known hypersensitivity to hyaluronan products or patients with infections in or around the knee. Use caution when using SYNVISC in patients allergic to avian proteins, feathers, or egg products; who have evidence of venous or lymphatic stasis in the leg to be treated; or who have severe inflammation in the knee joint to be treated. Patients should be advised to avoid strenuous or prolonged weight-bearing activities after treatment. Strict adherence to aseptic technique must be followed to avoid joint infection. The safety and effectiveness of SYNVISC in children and in pregnant or lactating women have not been established. It is unknown whether SYNVISC is excreted in human milk.

View the Complete Prescribing Information for SYNVISC (PDF, 146k)